Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Martinez Moreno, E. [1 ]
Irigoyen Medina, A. [1 ]
Alvarez Cabellos, R. [1 ]
Martinez, K. A. [1 ]
Santiago, J. [1 ]
Rivilla, M. [1 ]
Cardenas, J. D. [1 ]
Esteban, C. [1 ]
Trujillo, B. [1 ]
Rosero, A. [1 ]
Fernandez, L. [1 ]
Ramos, I. [1 ]
Ramos, A. [1 ]
Chacon, J. I. [1 ]
机构：
[1] Hosp Virgen de La Salud, Oncol Med, Toledo, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
chemotherapy; NSCLC; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.04-29
引用
收藏
页码：S536 / S537
页数：2
相关论文
共 50 条
  • [31] Nivolumab for Previously Treated Patients with Non-Small-Cell Lung Cancer-Daily Practice versus Clinical Trials
    Knetki-Wroblewska, Magdalena
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (07) : 1 - 10
  • [32] Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
    Jumpei Kashima
    Yusuke Okuma
    Ryoko Shimizuguchi
    Kazuro Chiba
    [J]. Cancer Immunology, Immunotherapy, 2018, 67 : 61 - 65
  • [33] Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report
    Kashima, Jumpei
    Okuma, Yusuke
    Shimizuguchi, Ryoko
    Chiba, Kazuro
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (01) : 61 - 65
  • [34] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [35] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    [J]. Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [36] Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study
    Wang, Yang
    Hao, Qianyun
    Nie, Jun
    Dai, Ling
    Hu, Weiheng
    Zhang, Jie
    Chen, Xiaoling
    Ma, Xiangjuan
    Tian, Guangming
    Han, Jindi
    Han, Sen
    Wu, Di
    Long, Jieran
    Zhang, Ziran
    Fang, Jian
    [J]. ANTI-CANCER DRUGS, 2024, 35 (05) : 412 - 417
  • [37] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25): : 2415 - 2426
  • [38] Nivolumab beyond First-Line (1L) Treatment in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Sotelo, Miguel
    Chara, Luis
    Riquelme, Alejandro
    Toro, Piedad
    Lopez, Cynthia
    Hernando, Susana
    Caviedes, Edinson
    Aguayo, Cristina
    Bueno, Coralia
    Mielgo Rubio, Xabier
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1340 - S1341
  • [39] Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line
    Mancuso, Patrizia
    Passaro, Antonio
    Labanca, Valentina
    Gandini, Sara
    Spitaleri, Gianluca
    Guerini, Elena
    Barberis, Massimo
    Noberasco, Cristina
    del Signore, Ester
    Pochesci, Alessia
    Catania, Chiara
    De Marinis, Filippo
    Bertolini, Francesco
    [J]. CANCER RESEARCH, 2017, 77
  • [40] Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
    Sugawara, S.
    Lee, J-S
    Kang, J-H
    Kim, H. R.
    Inui, N.
    Hida, T.
    Lee, K. H.
    Yoshida, T.
    Tanaka, H.
    Yang, C-T
    Nishio, M.
    Ohe, Y.
    Tamura, T.
    Yamamoto, N.
    Yu, C-J
    Akamatsu, H.
    Namba, Y.
    Sumiyoshi, N.
    Nakagawa, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (09) : 1137 - 1147
12345